GeoVax Labs Appoints Dr. Senthil Ranganathan to Lead Technical Development and CMC Operations
TL;DR
Dr. Ranganathan's expertise in biologics development gives GeoVax a competitive edge in advancing infectious disease vaccines and cancer therapies.
Dr. Ranganathan, with 20 years of experience, will lead technical development and CMC operations at GeoVax to commercialize vaccines and therapies.
GeoVax's appointment of Dr. Ranganathan aims to address medical needs, enhance biodefense readiness, and promote vaccine and therapeutic equity, benefiting global communities.
Dr. Ranganathan's career in biopharmaceuticals spans cell and gene therapies, vaccines, and more, contributing to innovative solutions in healthcare.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company known for its work in developing vaccines and immunotherapies for infectious diseases and cancer, has announced the appointment of Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations. This strategic hire is set to bolster the company's capabilities in biologics development, from vaccines to cell and gene therapies, as it aims to address unmet medical needs and enhance biodefense readiness.
Dr. Ranganathan's extensive experience, spanning over two decades in the biopharmaceutical industry, includes leadership roles at National Resilience, Athersys, Zymeworks, and Alder Biopharmaceuticals. His expertise in process development and manufacturing operations is expected to play a pivotal role in GeoVax's journey towards the authorization and commercialization of its development portfolio. David Dodd, Chairman & CEO of GeoVax, expressed enthusiasm about Dr. Ranganathan's joining, highlighting his potential to accelerate the company's progress in bringing innovative vaccines and therapies to market.
The appointment comes at a crucial time for GeoVax as it advances its portfolio, including GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, an oncolytic solid tumor gene-directed therapy. Dr. Ranganathan's track record in navigating the complexities of biologics development and commercialization is seen as a valuable asset for GeoVax's ambitious goals. His academic background, with a Ph.D. in Biochemistry from Loyola University Chicago, and his contributions to regulatory submissions and publications, further underscore his qualifications for the role.
Dr. Ranganathan shared his excitement about joining GeoVax, emphasizing the opportunity to contribute to the company's growth and the development of therapies that could benefit patients globally. With a strong IP portfolio and ongoing clinical trials, GeoVax is poised to make significant strides in the biotechnology sector, supported by Dr. Ranganathan's leadership in technical development and CMC operations. For more information on GeoVax's initiatives, visit https://www.geovax.com.
Curated from NewMediaWire
